ArticleFrontiers in immunology2026

Tocilizumab combined with short-term high-dose glucocorticoids for rapid disease activity control and glucocorticoid reduction in adult-onset Still's disease: a single-center retrospective study.

Shi-Lei Zhong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.